Shine forms therapeutics division

By staff writers

October 14, 2019 -- Medical isotope firm Shine Medical Technologies has launched Shine Therapeutics, a new division that will target the market for therapeutic isotopes.

Shine Therapeutics will initially focus on developing and commercializing lutetium-177 (Lu-177), but it is also evaluating additional medical isotopes with therapeutic properties, according to the company. Shine signed an agreement in May with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences to license a method for producing Lu-177.

Katrina Pitas has been named as vice president and general manager of the new division. A 10-year company veteran, Pitas previously served as Shine's vice president of business development.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking